Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Pharmala Biotech Holdings Inc. (MDMA.CN)

Pharmala Biotech Holdings Inc. (MDMA.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cortexa Advances Commercialisation of MDMA Supply in Australia GlobeNewswire - Mon Mar 23, 8:00AM CDT

MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading psychedelic medicines supplier, reaffirms its market leading position in FY2026 for MDMA (3,4-methylenedioxymethamphetamine)....

MDXXF : 0.0690 (-11.76%)
VIT.AX : 0.038 (-5.00%)
MDMA.CN : 0.1050 (+5.00%)
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders GlobeNewswire - Tue Mar 3, 8:00AM CST

TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA...

MDXXF : 0.0690 (-11.76%)
MDMA.CN : 0.1050 (+5.00%)
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia GlobeNewswire - Thu Feb 26, 7:26AM CST

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA...

MDXXF : 0.0690 (-11.76%)
MDMA.CN : 0.1050 (+5.00%)
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data GlobeNewswire - Mon Feb 23, 7:30AM CST

TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA...

MDXXF : 0.0690 (-11.76%)
MDMA.CN : 0.1050 (+5.00%)
PharmAla Announces Changes to Board of Directors GlobeNewswire - Tue Feb 10, 3:40PM CST

TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development,...

MDXXF : 0.0690 (-11.76%)
MDMA.CN : 0.1050 (+5.00%)
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research GlobeNewswire - Thu Jan 8, 7:30AM CST

TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development,...

MDXXF : 0.0690 (-11.76%)
MDMA.CN : 0.1050 (+5.00%)
PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements GlobeNewswire - Wed Dec 24, 2025

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development,...

MDXXF : 0.0690 (-11.76%)
MDMA.CN : 0.1050 (+5.00%)
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance GlobeNewswire - Mon Dec 15, 2025

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development,...

MDXXF : 0.0690 (-11.76%)
MDMA.CN : 0.1050 (+5.00%)
PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules GlobeNewswire - Wed Dec 10, 2025

TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development,...

MDXXF : 0.0690 (-11.76%)
MDMA.CN : 0.1050 (+5.00%)
PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital GlobeNewswire - Mon Nov 3, 2025

TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development,...

MDXXF : 0.0690 (-11.76%)
MDMA.CN : 0.1050 (+5.00%)

Barchart Exclusives

AMAT, LRCX: Bank of America Is Still Pounding the Table on These 2 Chip Stocks Barchart - 6 minutes ago
AMAT and LRCX still look like high‑conviction ways to play the AI and advanced‑node capex cycle, but they sit firmly in “quality growth at a premium” territory rather than obvious bargains. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.